Product
rIL-2
1 clinical trial
2 indications
Indication
NeuroblastomaIndication
High-RiskClinical trial
Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01